期刊
CELL
卷 184, 期 10, 页码 2595-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2021.03.061
关键词
-
资金
- CTSA grant [TL1 TR001864]
- Emergent Ventures at the Mercatus Center at George Mason University
- Centers for Disease Control and Prevention (CDC) [75D30120C09570, 75D30120C09870]
- New York Community Trust
The study found that the SARS-CoV-2 B.1.1.7 variant primarily spread in the United States through ports of entry in New York, California, and Florida, with multiple independent establishments starting in early December 2020 and interstate spread by the end of the month. It is projected that B.1.1.7 will become the dominant lineage in many states by mid- to late March, highlighting the urgent need to enhance genomic surveillance.
The emergence and spread of SARS-CoV-2 lineage B.1.1.7, first detected in the United Kingdom, has become a global public health concern because of its increased transmissibility. Over 2,500 COVID-19 cases associated with this variant have been detected in the United States (US) since December 2020, but the extent of establishment is relatively unknown. Using travel, genomic, and diagnostic data, we highlight that the primary ports of entry for B.1.1.7 in the US were in New York, California, and Florida. Furthermore, we found evidence for many independent B.1.1.7 establishments starting in early December 2020, followed by interstate spread by the end of the month. Finally, we project that B.1.1.7 will be the dominant lineage in many states by mid- to late March. Thus, genomic surveillance for B.1.1.7 and other variants urgently needs to be enhanced to better inform the public health response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据